A woman who inherits these mutations faces 60 to 80 percent increased likelihood of developing breast cancer.
Em um passo que aproxima a medicina de precisão da saúde coletiva, o Brasil decidiu incorporar ao SUS o teste genético para mutações BRCA1 e BRCA2 — marcadores associados a um risco de 60 a 80% de desenvolvimento de câncer de mama. A medida, anunciada pelo Ministério da Saúde após avaliação da Conitec, transforma um recurso antes restrito à medicina privada em direito acessível a milhões de brasileiras. Com prazo de 180 dias para implementação, o país sinaliza uma virada em direção à oncologia preventiva e personalizada no âmbito público.
- Mulheres sem condições de arcar com exames privados enfrentavam uma lacuna diagnóstica crítica: a mesma tecnologia que poderia salvar suas vidas estava disponível apenas para quem podia pagar.
- A incorporação do teste ao SUS rompe essa barreira, colocando o rastreamento genético de alto risco ao alcance de pacientes atendidas em clínicas e hospitais públicos de todo o país.
- A decisão exige agora uma corrida logística: 27 estados precisam criar protocolos, capacitar equipes e integrar o exame aos fluxos diagnósticos existentes dentro de seis meses.
- O impacto vai além das pacientes já diagnosticadas — identificar uma mutação em uma mulher abre caminho para que familiares busquem aconselhamento genético e medidas preventivas antes que o câncer se desenvolva.
- O horizonte aponta para uma medicina pública mais preditiva: o teste pode reduzir a mortalidade por câncer de mama ao antecipar intervenções em populações historicamente desassistidas.
O Ministério da Saúde do Brasil anunciou na quarta-feira a incorporação do teste genético para mutações BRCA1 e BRCA2 ao Sistema Único de Saúde, tornando o exame gratuito para pacientes atendidas na rede pública. A decisão foi formalizada por decreto da Secretaria de Ciência, Tecnologia e Inovação em Saúde, após avaliação da Conitec, comissão responsável por revisar novas tecnologias antes de sua entrada no sistema público. O governo estabeleceu um prazo de 180 dias para a implantação em todas as áreas técnicas do país.
Os genes BRCA1 e BRCA2 atuam como supressores tumorais: quando funcionam normalmente, reparam danos no DNA e impedem a multiplicação de células comprometidas. Quando carregam mutações, esse mecanismo de proteção falha, elevando em 60 a 80% o risco de uma mulher desenvolver câncer de mama ao longo da vida, segundo o oncologista Oren Smaletz, do Hospital Israelita Einstein. Como essas mutações são hereditárias, identificá-las em uma paciente também alerta seus familiares sobre a própria vulnerabilidade.
Num primeiro momento, o teste será direcionado a mulheres já diagnosticadas com câncer de mama, auxiliando médicos a compreender a base genética da doença e personalizar o tratamento. Mas os efeitos se expandem: familiares que descobrem carregar a mutação podem adotar medidas preventivas — exames de imagem mais frequentes, ressonâncias magnéticas ou, em alguns casos, cirurgias profiláticas — antes que o câncer se manifeste.
Antes dessa decisão, o teste estava disponível no Brasil principalmente em clínicas privadas, a custos elevados. A incorporação ao SUS significa que mulheres sem recursos financeiros terão acesso à mesma precisão diagnóstica. A implementação deve ser gradual, começando pelos grandes centros urbanos antes de alcançar cidades menores e regiões rurais — mas o compromisso está firmado: em seis meses, o Brasil deverá oferecer publicamente uma ferramenta que, até agora, pertencia quase exclusivamente a quem podia pagar por ela.
Brazil's public health system will soon offer genetic testing that can identify whether a woman carries mutations in two genes strongly linked to breast cancer. The Health Ministry announced the decision on Wednesday, incorporating a high-precision test for BRCA1 and BRCA2 mutations into the SUS—the country's unified health system—making the technology available free of charge to patients already receiving care in public clinics and hospitals. The government has set a 180-day window to roll out the test across all technical areas of the system nationwide.
The announcement came through an official decree issued by the Ministry's Secretariat of Science, Technology, and Health Innovation. The decision followed a formal evaluation by Conitec, the National Commission for Technology Incorporation in the Unified Health System, which reviews new medical devices and diagnostic tools before they enter the public health network. This particular test represents a significant expansion of precision medicine tools available to Brazilians who depend on public healthcare.
The genes in question—BRCA1 and BRCA2—function as tumor suppressors. They normally repair damage in DNA, preventing cells with corrupted genetic material from multiplying. When these genes carry mutations, that protective mechanism fails. A woman who inherits one of these mutations faces a 60 to 80 percent increased likelihood of developing breast cancer at some point in her life, according to Dr. Oren Smaletz, an oncologist at Einstein Hospital Israelita. That elevated risk extends beyond the individual patient. Because these mutations can be inherited, identifying them in one family member alerts relatives to their own potential vulnerability.
The test will initially focus on women already diagnosed with breast cancer, helping doctors understand the genetic underpinnings of their disease and tailor treatment accordingly. But the implications ripple outward. Once a woman learns she carries a BRCA mutation, her family members can pursue genetic counseling and their own testing. Those who discover they carry the mutation themselves can take preventive steps—more frequent imaging, magnetic resonance scans, or in some cases, preventive surgery—before cancer develops. For families with a history of breast cancer, this kind of early warning system can reshape medical decisions and outcomes.
Before this announcement, genetic testing for BRCA mutations was available in Brazil, but primarily through private clinics and at significant cost. Incorporating it into the SUS means that women without the means to pay out of pocket will now have access to the same diagnostic precision. The test detects the specific genetic sequences associated with heightened cancer risk, allowing doctors and patients to make informed choices about prevention and early detection. For a country where breast cancer remains a leading cause of cancer death among women, expanding access to this tool represents a shift toward personalized, preventive medicine at the population level.
The 180-day implementation timeline will determine how quickly the test becomes available in practice. Health systems across Brazil's 27 states will need to establish protocols, train staff, and integrate the testing into their existing diagnostic workflows. The rollout will likely be gradual, beginning in larger urban centers before reaching smaller cities and rural areas. But the commitment is now formal: within six months, Brazilian women in the public health system should be able to access a test that, until now, has been largely confined to those who could afford private care.
Notable Quotes
Those who inherit these genes have a 60 to 80 percent greater chance of developing this type of cancer— Dr. Oren Smaletz, oncologist at Einstein Hospital Israelita
The Hearth Conversation Another angle on the story
Why does it matter that this test is being added to the public system now, rather than staying private?
Because breast cancer doesn't care about your bank account. Right now, only wealthy Brazilians can afford this test. Everyone else is flying blind. Adding it to SUS means a woman in a small town gets the same genetic insight as someone in São Paulo.
But the test itself isn't new. What changed?
The technology existed, yes. But Conitec had to evaluate whether it was worth the public investment—whether the benefit to patients justified the cost. They decided it does. That's the shift. The science was always there; the political will to make it universal is new.
What happens to a woman who finds out she carries a BRCA mutation?
Everything changes. She knows her risk is real and quantifiable. She can see a genetic counselor, talk to her family, make decisions about screening frequency or even preventive surgery. Her relatives can get tested too. It's not just diagnosis; it's foreknowledge.
Is there a downside to knowing?
Psychological burden, certainly. Some women live with the knowledge that they have a high probability of developing cancer but may never get it. There's also the question of access to preventive care—knowing your risk is one thing; being able to afford preventive surgery is another. But the Ministry seems to be betting that knowledge, even difficult knowledge, is better than ignorance.
How long before this actually reaches patients?
Six months in theory. In practice, it depends on how quickly each state health system can set up the infrastructure. Urban centers will move faster. Rural areas will lag. But the commitment is there now.